Novo Nordisk A/SNVONYSE
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank41
3Y CAGR-67.7%
5Y CAGR-49.1%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-67.7%/yr
vs +63.2%/yr prior
5Y CAGR
-49.1%/yr
Recent deceleration
Acceleration
-130.9pp
Decelerating
Percentile
P41
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 0.66% |
| Q3 2025 | -8.10% |
| Q2 2025 | 16.99% |
| Q1 2025 | -20.56% |
| Q4 2024 | 22.23% |
| Q3 2024 | 3.11% |
| Q2 2024 | 11.64% |
| Q1 2024 | -22.62% |
| Q4 2023 | 32.33% |
| Q3 2023 | -8.69% |
| Q2 2023 | 14.32% |
| Q1 2023 | -10.66% |
| Q4 2022 | 19.68% |
| Q3 2022 | 6.58% |
| Q2 2022 | 6.08% |
| Q1 2022 | -13.02% |
| Q4 2021 | 26.41% |
| Q3 2021 | 13.90% |
| Q2 2021 | -3.08% |
| Q1 2021 | -16.20% |
| Q4 2020 | 19.43% |
| Q3 2020 | 11.61% |
| Q2 2020 | -3.43% |
| Q1 2020 | -20.93% |
| Q4 2019 | 22.82% |
| Q3 2019 | 4.01% |
| Q2 2019 | 7.32% |
| Q1 2019 | -21.41% |
| Q4 2018 | 24.03% |
| Q3 2018 | 1.50% |
| Q2 2018 | 8.56% |
| Q1 2018 | -22.29% |
| Q4 2017 | 27.32% |
| Q3 2017 | -2.95% |
| Q2 2017 | -1.06% |
| Q1 2017 | -15.15% |
| Q4 2016 | 15.24% |
| Q3 2016 | 1.74% |
| Q2 2016 | 1.19% |
| Q1 2016 | -16.89% |